Description
• TRIOS Dx Plus: Redefining diagnostics with AI-assisted aid for objective, consistent results
Exclusive to TRIOS 6 scans, pending FDA approval, it will be possible to deliver reliable, trusted
experiences with AI-assistive TRIOS Dx Plus software, redefining diagnostics for accurate, objective
identification of key oral health conditions – including proximal* and surface caries, plaque, tooth wear
and gingival recession. (*Proximal caries is not AI-enabled).
Dx Plus has the potential to be disruptive to the dental industry and requires a De Novo approval process
by the FDA. Currently, we expect to receive FDA approval during Q1, 2026. Dx Plus will exclusively be
compatible with TRIOS 6 and available free of charge for 6 months upon activation and regulatory
approval. Pricing for Dx Plus will be communicated separately during Q3 2025.
Reviews
There are no reviews yet.